Medication Assisted Treatment

Evidence Ranking: Proven

In this featured collection, we put a spotlight on medication assisted treatment (MAT) for opioid use disorder (OUD). Research has proven that MAT is an evidence-based strategy for treating individuals with OUD; individuals who use MAT as part of their treatment and recovery plan are more likely to be retained in treatment and to have fewer adverse events such as opioid overdose and opioid overdose mortality.

Featured Collection
Policymakers & Community Leaders
Patients & Caregivers

Medications for Opioids Use Disorder Save Lives

Evidence Ranking: Proven

Source: National Academies of Science Engineering and Medicine

This 2 minute video accompanies the National Academies of Science, Engineering and Medicine’s report Medications for Opioid Use Disorder Save Lives.

Video
Policymakers & Community Leaders
Payers & Providers

Spotlight: Yale Emergency Department Treatment Initiation

Evidence Ranking: Promising

Source: Addiction Policy Forum

A brief overview of the emergency department (ED) based induction to buprenorphine program initiated at Yale New Haven Hospital. This report describes a randomized controlled trial that provided patients with opioid use disorder seen in the emergency room with either a substance use disorder screening and referral to treatment, a screening and brief intervention with facilitated referral to treatment, or induction to buprenorphine medicated assisted treatment and a referral to follow up treatment. Those patients offered buprenorphine were significantly more likely to be engaged in treatment 30 days later than the other patients. This model has subsequently been adopted in EDs across the country. This report is part of the Addiction Policy Forum’s Spotlight series which highlights innovative programs to address the opioid crisis.

Document
Policymakers & Community Leaders
Payers & Providers

Translating Local Innovation Into Statewide Policy: Lessons From a Medications for Addiction Treatment (MAT) Prior Authorization Pilot in Camden, New Jersey

Evidence Ranking: Promising

Source: Camden Coalition of Health Care Providers

In 2017 the Camden Coalition of Healthcare Providers began a pilot in partnership with local addiction treatment providers and UnitedHealthCare to see if removing prior authorization requirements for buprenorphine would reduce barriers to treatment and improve patient and system outcomes.

Document
Policymakers & Community Leaders
Payers & Providers

Policy Evaluation: Substance Use Disorders

Evidence Ranking: Proven

Source: Oregon Health Authority

This 2019 review from Oregon’s Drug Use Research & Management Program examined whether removing Medicaid prior authorization requirements for medication assisted treatment for individuals with opioid use

Document
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

Medications for Opioid Use Disorder Save Lives: Consensus Study Report – Highlights

Evidence Ranking: Proven

Source: National Academies of Science, Engineering, and Medicine

This four page document presents the highlights from the 2019 National Academies report on medication assisted treatment for opioid use disorder. Funding Source: National Institute on Drug Abuse, National Institutes of Health; Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services

Document